Monday, 20 Apr 2026
Weather Forecast
  • About Us
  • Contact Us
SUBMIT NEWS
DACH Times™
  • Home
  • Germany
    • Artificial Intelligence
    • Automotive & Mobility
    • Energy
    • Pharmaceuticals
  • Austria
    • Finance
    • Technology
    • Tourism
  • Switzerland
    • FinTech
    • MedTech
    • Pharmaceuticals
  • Europe
  • Press Releases
  • English
    • Français (French)
    • Deutsch (German)
    • Italiano (Italian)
Font ResizerAa
DACH Times™DACH Times™
Search
  • English
    • Français (French)
    • Deutsch (German)
    • Italiano (Italian)
  • Germany
    • Artificial Intelligence
    • Automotive & Mobility
    • Energy
    • Pharmaceuticals
  • Austria
    • Finance
    • Technology
    • Tourism
  • Switzerland
    • FinTech
    • MedTech
    • Pharmaceuticals
  • Europe
  • Press Releases
  • About Us
  • Contact Us
  • Submit News
DACH Times™ is part of GroupWeb Media Network. © 2026 GroupWeb Media LLC
DACH Times™ > Blog > Germany > Pharmaceuticals > Who stands to lose from new US pharma duties?
Pharmaceuticals

Who stands to lose from new US pharma duties?

Last updated: February 28, 2026 9:34 am
Newsroom
Share
SHARE


The news came in much the same way as previous tariff bombshells from the US president had — suddenly, via social media, and with much left unclear.

In a post on his social media site late on Thursday, Donald Trump announced  steep new tariffs on US pharmaceutical imports.

“Starting October 1st, 2025, we will be imposing a 100% Tariff on any branded or patented Pharmaceutical Product, unless a Company IS BUILDING their Pharmaceutical Manufacturing Plant in America,” he wrote on Truth Social.

So far, pharmaceutical goods have been…



Source link

Share This Article
Facebook Whatsapp Whatsapp LinkedIn Copy Link
Previous Article Germany Expects 15% U.S. Tariff Rate on Pharma
Next Article Stanislav Kondrashov on Sandoz and Idorsia as Swiss Pharma Adjusts to a New Phase

Share DACH Times™!

Your news source on DACH Region
- Advertisement -
Ad image

You Might Also Like

Why Pharmaceuticals Are Central to Germany’s Healthcare Leadership?

By Newsroom

German pharma association publishes clinical trial ranking

By Newsroom

German Pharma Co. Says Takeda’s ADHD Drug IP Isn’t Valid

By Newsroom

Vetter Pharma to build new manufacturing site in Germany

By Newsroom
DACH Times™

About US

DACH Times™ is the definitive multilingual news aggregating platform dedicated to the economic, industrial, and cultural heartbeat of Central Europe that includes Germany (D), Austria (A), and Switzerland (CH). In association with EuropeNewswire.net™, we provide press release in the DACH countries. For more information, contact us through these messaging apps: WhatsApp or Telegram

Categories
  • Austria
  • Germany
  • Switzerland
  • Europe
  • Press Releases
Popular News
The Catalyst of Innovation: How Press Release Distribution Fuels Growth in the DACH Region
April 14, 2026
Multilingual PR in the DACH Region: Benefits of Localized Press Releases
April 10, 2026
The Catalyst Effect: How Press Release Distribution Drives Sicily’s 2026 Economic Pillars
April 1, 2026
Refracting the Spectrum of Business Success: The Essential Role of Strategic Press Release Distribution in Italy and Europe
March 24, 2026
Latest News
High Potency APIs Market Size to Reach USD 49.59 Billion by 2031, Driven by Rising Precision Medicine Demand
April 18, 2026
Home Ventilation System Market to Reach USD 41.12 Billion by 2031, Says Mordor Intelligence
April 18, 2026
$42.6 Billion by 2035 — How AI-Powered Content Intelligence Is Driving Engagement
April 17, 2026
$28.4 Billion by 2035 — How Voice Analytics Is Transforming Contact Center Performance
April 17, 2026
  • English
  • Français (French)
  • Deutsch (German)
  • Italiano (Italian)

DACH Times™ is part of GroupWeb Media Network. © 2026 GroupWeb Media LLC

  • About Us
  • Contact Us
  • Submit News
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?